Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.9800 (-1.32%) ($5.9800 - $5.9800) on Fri. Feb. 5, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.69% (three month average) | RSI | 71 | Latest Price | $5.9800(-1.32%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS advances 0.5% a day on average for past five trading days. | Weekly Trend | ADMS advances 13.7% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) UNG(21%) TLT(11%) SIL(22%) SLV(18%) VIXM(11%) | Factors Impacting ADMS price | ADMS will decline at least -2.345% in a week (0% probabilities). JETS(-24%) CEMB(-18%) EWP(-16%) XLE(-15%) REMX(-15%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -2.345% (StdDev 4.69%) | Hourly BBV | 0.5 () | Intraday Trend | 0% | | | |
|
Inflection Point | Yes | 5 Day Moving Average | $5.98(0%) | 10 Day Moving Average | $5.75(4%) | 20 Day Moving Average | $5.18(15.44%) | To recent high | -10.2% | To recent low | 19.6% | Market Cap | $169m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |